SFI
PMVP icon

Susquehanna Fundamental Investments’s PMV Pharmaceuticals PMVP Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-33,568
Closed -$775K – 1657
2021
Q4 		$775K Buy
+33,568
New +$811K 0.02% 749

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Susquehanna Fundamental Investments's PMVP Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of PMV Pharmaceuticals (PMVP) in Q1 2022, closing a stake of 33,568 shares — an estimated $775K sold.

Susquehanna Fundamental Investments first reported a position in PMVP in Q4 2021 and held it in 1 quarter. The position peaked at $775K in Q4 2021. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2022.

  • Susquehanna Fundamental Investments reported no remaining PMV Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 33,568 PMV Pharmaceuticals shares in Q1 2022, an estimated $775K.
  • Susquehanna Fundamental Investments first reported a position in PMV Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's PMV Pharmaceuticals position peaked at $775K in Q4 2021.
  • 99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.